why is my semaglutide red for Weight Loss FAQ's Weight Loss Drug Semaglutide side effects go beyond

Cardiovascular Evidence# LEADER Trial (Liraglutide)# The LEADER trial (Marso et al., NEJM 2016) enrolled 9,340 patients with T2D and high CV risk, followed for median 3.8 years: 3-point MACE: HR 0.87 (95% CI 0.78-0.97, p=0.01) -- 13% reduction Cardiovascular death: HR 0.78 (22% reduction) All-cause mortality: HR 0.85 (15% reduction) Liraglutide was the first GLP-1 agonist to demonstrate cardiovascular benefit, and LEADER remains a landmark trial in the class

Home gym equipment, community center memberships, or simply creative use of stairs and bodyweight exercises keep activity levels consistent regardless of weather

Keep out of the reach of small children

64 In the STEP-HFpEF study, the incidence of AF and atrial flutter was lower in the semaglutide group than in the placebo group (1.1% versus 3.4% and 0% versus 1.1%, respectively)

These drugs have not been adequately studied in pregnant women, and animal studies have raised concerns about fetal development

doi: 10.1007/s10067-023-06612-w